You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDicyclomine
Accession NumberDB00804  (APRD00113)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]
Structure
Thumb
Synonyms
2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester
Dicicloverina
DICYCLOMINE
Dicycloverin
Dicycloverine
Dicycloverinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bentylcapsule10 mg/1oralAptalis Pharma US, Inc.1950-05-11Not applicableUs
Bentyltablet20.6 mg/1oralAptalis Pharma US, Inc.1950-05-11Not applicableUs
Bentylinjection, solution20 mg/2mLintramuscularAptalis Pharma US, Inc.1952-08-13Not applicableUs
Bentylolsyrup10 mgoralAptalis Pharma Canada Inc1993-12-31Not applicableCanada
Bentylol Dospan 30mgtablet (extended-release)30 mgoralMerrell Pharms Inc., Division Of Merrell Dow (Can)1988-03-231996-09-09Canada
Bentylol Inj 10mg/mlliquid10 mgintramuscularMerrell Pharms Inc., Division Of Merrell Dow (Can)1965-12-311996-09-09Canada
Bentylol Tablet 10mgtablet10 mgoralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Bentylol Tablet 20mgtablet20 mgoralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Dicyclomine Cap 10mgcapsule10 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Dicyclomine Hydrochloride Injection USPsolution10 mgintramuscularSandoz Canada Incorporated1976-12-31Not applicableCanada
Dicyclomine Hydrochloride USPcapsule10 mgoralSandoz Canada Incorporated1976-12-31Not applicableCanada
Formulex Cap 10mgcapsule10 mgoralValeant Canada Lp Valeant Canada S.E.C.1977-12-312014-07-30Canada
Jamp-dicyclomine HCltablet10 mgoralJamp Pharma Corporation2012-10-23Not applicableCanada
Jamp-dicyclomine HCltablet20 mgoralJamp Pharma Corporation2011-08-08Not applicableCanada
Protylol Cap 10mgcapsule10 mgoralPro Doc Limitee1974-12-31Not applicableCanada
Protylol Tab 20mgtablet20 mgoralPro Doc Limitee1981-12-312014-07-24Canada
Riva-dicyclominecapsule10 mgoralLaboratoire Riva Inc1982-12-31Not applicableCanada
Viscerol Cap 10mgcapsule10 mgoralMedic Laboratory LtÉe1974-12-311996-09-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dicyclominetablet20 mg/1oralWest ward Pharmaceutical Corp1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Dicyclominetablet20 mg/1oralH.J. Harkins Company, Inc.1996-10-01Not applicableUs
Dicyclominecapsule10 mg/1oralRebel Distributors Corp.1997-02-28Not applicableUs
Dicyclominecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-02-28Not applicableUs
Dicyclominetablet20 mg/1oralA S Medication Solutions1996-10-01Not applicableUs
Dicyclominecapsule10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclominetablet20 mg/1oralLiberty Pharmaceuticals, Inc.1996-10-01Not applicableUs
Dicyclominecapsule10 mg/1oralGolden State Medical Supply, Inc.1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralPreferred Pharmaceuticals, Inc1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralbryant ranch prepack1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralMajor Pharmaceuticals1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralSTAT Rx USA LLC1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralGolden State Medical Supply, Inc.1996-10-01Not applicableUs
Dicyclominetablet20 mg/1oralREMEDYREPACK INC.2013-03-152016-04-05Us
Dicyclominetablet20 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralA S Medication Solutions Llc1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2015-01-022016-04-05Us
Dicyclomine Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralLannett Company, Inc.1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-21Not applicableUs
Dicyclomine Hydrochloridesolution10 mg/5mLoralAtlantic Biologicals Corps2005-06-23Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralPd Rx Pharmaceuticals, Inc.1986-07-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralMylan Institutional Inc.1998-03-06Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralProficient Rx LP1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-07-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2013-02-13Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralA S Medication Solutions Llc1986-07-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralSt. Mary's Medical Park Pharmacy1986-07-30Not applicableUs
Dicyclomine Hydrochloridesolution10 mg/5mLoralQualitest Pharmaceuticals2005-06-23Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralLife Line Home Care Services, Inc.2012-02-07Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralMylan Pharmaceuticals Inc.2013-03-27Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralTYA Pharmaceuticals1974-09-30Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2010-11-20Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralCardinal Health2011-08-16Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralA S Medication Solutions Llc1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralClinical Solutions Wholesale1986-07-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralLannett Company, Inc.1999-02-26Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralPreferred Pharmaceuticals, Inc.2013-02-18Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2013-03-09Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralA S Medication Solutions Llc1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralWest ward Pharmaceutical Corp1997-02-28Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralProficient Rx LP1999-02-26Not applicableUs
Dicyclomine Hydrochlorideinjection10 mg/mLintramuscularWest Ward Pharmaceuticals Corp.2015-12-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2015-01-24Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralAidarex Pharmaceuticals LLC1999-02-26Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralA S Medication Solutions Llc1999-02-26Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2013-07-09Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralCardinal Health2011-08-16Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralDispensing Solutions, Inc.1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralStat Rx USA1997-02-28Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-18Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralA S Medication Solutions Llc1986-06-19Not applicableUs
Dicyclomine Hydrochloridesyrup10 mg/mLoralEntera Health, Inc.2015-04-27Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralActavis Pharma, Inc.1986-06-19Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralRebel Distributors Corp1999-02-26Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.1995-10-26Not applicableUs
Dicyclomine Hydrochloridesolution10 mg/5mLoralKAISER FOUNDATION HOSPITALS2015-04-02Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralUnit Dose Services1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralAidarex Pharmaceuticals LLC1974-09-30Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1974-09-30Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2013-10-15Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralLiberty Pharmaceuticals, Inc.1974-09-30Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralPreferred Pharmaceuticals Inc.2015-05-13Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralA S Medication Solutions Llc1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralActavis Pharma, Inc.1986-07-30Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralPreferred Pharmaceuticals, Inc2012-01-17Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2010-07-23Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2013-06-242016-04-05Us
Dicyclomine Hydrochloridetablet20 mg/1oralPhysicians Total Care, Inc.1995-01-23Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralMylan Pharmaceuticals Inc.2013-03-27Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralbryant ranch prepack1997-02-28Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralMylan Institutional Inc.1999-12-01Not applicableUs
Dicyclomine Hydrochloridetablet20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-06-19Not applicableUs
Dicyclomine Hydrochloridecapsule10 mg/1oralRebel Distributors Corp1986-06-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ByclomineNot Available
Di-SpazNot Available
DibentNot Available
DilomineNot Available
DyspasSavage
MerbentylSanofi
Brand mixtures
NameLabellerIngredients
DiclophenPro Doc Limitee
Spasmo Nil TabDuchesnay Inc
Salts
Name/CASStructureProperties
Dicyclomine Hydrochloride
Thumb
  • InChI Key: GUBNMFJOJGDCEL-UHFFFAOYSA-N
  • Monoisotopic Mass: 345.243457108
  • Average Mass: 345.948
DBSALT000698
Categories
UNII4KV4X8IF6V
CAS number77-19-0
WeightAverage: 309.4867
Monoisotopic: 309.266779369
Chemical FormulaC19H35NO2
InChI KeyInChIKey=CURUTKGFNZGFSE-UHFFFAOYSA-N
InChI
InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
SMILES
CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carboxylic acid esters. These are carboxylic acid derivatives in which the carbo atom from the carbonyl group is attached to an alkyl or an aryl moiety through an oxygen atom (forming an ester group).
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentCarboxylic acid esters
Alternative Parents
Substituents
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic homomonocyclic compound
Molecular FrameworkAliphatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of functional bowel/irritable bowel syndrome including Colicky abdominal pain; diverticulitis
PharmacodynamicsDicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.
Mechanism of actionAction is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).
Related Articles
AbsorptionNot Available
Volume of distribution
  • 3.65 L/kg [20 mg oral dose]
Protein binding>99%
MetabolismNot Available
Route of eliminationThe principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%).
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9769
Caco-2 permeable+0.6616
P-glycoprotein substrateSubstrate0.6141
P-glycoprotein inhibitor INon-inhibitor0.6115
P-glycoprotein inhibitor IINon-inhibitor0.5806
Renal organic cation transporterInhibitor0.5184
CYP450 2C9 substrateNon-substrate0.8373
CYP450 2D6 substrateNon-substrate0.8226
CYP450 3A4 substrateSubstrate0.5092
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6193
Ames testNon AMES toxic0.8524
CarcinogenicityNon-carcinogens0.52
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity3.1919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.873
hERG inhibition (predictor II)Inhibitor0.6714
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Axcan pharma us inc
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pioneer pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Bedford laboratories div ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Mikart inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular20 mg/2mL
Tabletoral20.6 mg/1
Syruporal10 mg
Tablet (extended-release)oral30 mg
Liquidintramuscular10 mg
Tabletoral10 mg
Tabletoral20 mg
Capsuleoral
Tabletoral20 mg/1
Capsuleoral10 mg/1
Injectionintramuscular10 mg/mL
Solutionoral10 mg/5mL
Syruporal10 mg/mL
Tabletoral10 mg/1
Solutionintramuscular10 mg
Capsuleoral10 mg
Tabletoral
Prices
Unit descriptionCostUnit
Bentyl 10 mg/ml ampul12.28USD ml
Dicyclomine 10 mg/ml vial8.58USD ml
Dicyclomine Hydrochloride 10 mg/ml3.41USD ml
Dicyclomine hcl powder1.0USD g
Bentyl 10 mg capsule0.79USD capsule
Bentyl 20 mg tablet0.75USD tablet
Dicyclomine HCl 10 mg capsule0.47USD capsule
Dicyclomine HCl 20 mg tablet0.4USD tablet
Dicyclomine 20 mg tablet0.31USD tablet
Bentylol 20 mg Tablet0.23USD tablet
Bentyl 10 mg/5ml Syrup0.15USD ml
Bentylol 10 mg Tablet0.12USD tablet
Dicyclomine HCl 10 mg/5ml Solution0.1USD ml
Bentylol 2 mg/ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point165-166Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.
logP5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP5.82ALOGPS
logP4.93ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.78 m3·mol-1ChemAxon
Polarizability37.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to
The Wm. S. Merrell Company.

General ReferencesNot Available
External Links
ATC CodesA03AA07
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Dicyclomine.
AclidiniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dicyclomine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dicyclomine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.
BenactyzineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dicyclomine.
BezitramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Biperiden.
Botulinum Toxin Type ADicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Chlorphenoxamine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.
CimetropiumDicyclomine may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.
CoumaphosThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Cyclopentolate.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.
DecamethoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Dichlorvos.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Dicyclomine is combined with DPDPE.
DronabinolDicyclomine may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Edrophonium.
EluxadolineDicyclomine may increase the constipating activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dicyclomine.
EthylmorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.
GalantamineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dicyclomine.
Ginkgo bilobaThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dicyclomine.
GlycopyrroniumDicyclomine may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.
HydrocodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.
HydromorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
IsoflurophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dicyclomine.
KetobemidoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Lofentanil.
MalathionThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dicyclomine.
MefloquineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.
MetixeneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.
MianserinMianserin may increase the anticholinergic activities of Dicyclomine.
MinaprineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with N-butylscopolammonium bromide.
NabiloneDicyclomine may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Dicyclomine is combined with NVA237.
OpiumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Orphenadrine.
OxybutyninThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dicyclomine.
PancuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.
PentazocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Dicyclomine.
Potassium ChlorideDicyclomine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Dicyclomine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.
PyridostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.
QuinidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.
RamosetronDicyclomine may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.
SolifenacinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.
TacrineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.
TiotropiumDicyclomine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dicyclomine.
TolterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.
TrimethaphanThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dicyclomine.
TubocurarineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Dicyclomine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.
Food Interactions
  • Avoid alcohol.
  • Take this medication 30 minutes before meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Jin CH, Shin EJ, Park JB, Jang CG, Li Z, Kim MS, Koo KH, Yoon HJ, Park SJ, Choi WC, Yamada K, Nabeshima T, Kim HC: Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Dec;87(16):3658-70. doi: 10.1002/jnr.22159. [PubMed:19533734 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14. [PubMed:9059856 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23